SVCM
APLS

Saturn V Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Saturn V Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-71,463
Closed -$4.2M – 27
2024
Q1 		$4.2M Sell
71,463
-71,464
-50% -$4.56M 1.68% 18
2023
Q4 		$8.56M Buy
+142,927
New +$7.25M 3.27% 13
2023
Q3 		– Sell
-107,406
Closed -$9.78M – 21
2023
Q2 		$9.78M Sell
107,406
-15,759
-13% -$1.36M 5.43% 9
2023
Q1 		$8.12M Sell
123,165
-89,164
-42% -$5.14M 6.07% 11
2022
Q4 		$9.41M Buy
+212,329
New +$11.3M 7.81% 3

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Saturn V Capital Management's APLS Position: Q2 2024 in Review

Saturn V Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2024, closing a stake of 71,463 shares — an estimated $4.2M sold.

Saturn V Capital Management first reported a position in APLS in Q4 2022 and held it in 5 quarters. The position peaked at $9.78M in Q2 2023. 263 funds tracked by Wall St. Rank hold APLS as of Q2 2024.

  • Saturn V Capital Management reported no remaining Apellis Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Saturn V Capital Management sold 71,463 Apellis Pharmaceuticals shares in Q2 2024, an estimated $4.2M.
  • Saturn V Capital Management first reported a position in Apellis Pharmaceuticals in Q4 2022 and held it in 5 quarters.
  • Saturn V Capital Management's Apellis Pharmaceuticals position peaked at $9.78M in Q2 2023.
  • 263 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2024.

Based on Saturn V Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.